JP2011006431A5 - - Google Patents

Download PDF

Info

Publication number
JP2011006431A5
JP2011006431A5 JP2010177518A JP2010177518A JP2011006431A5 JP 2011006431 A5 JP2011006431 A5 JP 2011006431A5 JP 2010177518 A JP2010177518 A JP 2010177518A JP 2010177518 A JP2010177518 A JP 2010177518A JP 2011006431 A5 JP2011006431 A5 JP 2011006431A5
Authority
JP
Japan
Prior art keywords
ataxia
adenosine
medicament
prevention
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010177518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011006431A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011006431A publication Critical patent/JP2011006431A/ja
Publication of JP2011006431A5 publication Critical patent/JP2011006431A5/ja
Pending legal-status Critical Current

Links

JP2010177518A 2002-12-19 2010-08-06 アデノシンＡ２ａレセプターアンタゴニストの使用 Pending JP2011006431A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43532102P 2002-12-19 2002-12-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005510511A Division JP2006514697A (ja) 2002-12-19 2003-12-17 アデノシンＡ２ａレセプターアンタゴニストの使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013013961A Division JP2013136592A (ja) 2002-12-19 2013-01-29 アデノシンＡ２ａレセプターアンタゴニストの使用

Publications (2)

Publication Number Publication Date
JP2011006431A JP2011006431A (ja) 2011-01-13
JP2011006431A5 true JP2011006431A5 (enExample) 2011-09-15

Family

ID=34572685

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2005510511A Withdrawn JP2006514697A (ja) 2002-12-19 2003-12-17 アデノシンＡ２ａレセプターアンタゴニストの使用
JP2010177518A Pending JP2011006431A (ja) 2002-12-19 2010-08-06 アデノシンＡ２ａレセプターアンタゴニストの使用
JP2013013961A Withdrawn JP2013136592A (ja) 2002-12-19 2013-01-29 アデノシンＡ２ａレセプターアンタゴニストの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2005510511A Withdrawn JP2006514697A (ja) 2002-12-19 2003-12-17 アデノシンＡ２ａレセプターアンタゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013013961A Withdrawn JP2013136592A (ja) 2002-12-19 2013-01-29 アデノシンＡ２ａレセプターアンタゴニストの使用

Country Status (15)

Country Link
US (2) US7414058B2 (enExample)
EP (3) EP2269596A3 (enExample)
JP (3) JP2006514697A (enExample)
CN (2) CN100415217C (enExample)
AT (1) ATE490775T1 (enExample)
AU (2) AU2003304527B2 (enExample)
BR (1) BR0317436A (enExample)
DE (1) DE60335294D1 (enExample)
ES (1) ES2354875T3 (enExample)
MX (1) MXPA05006790A (enExample)
NO (1) NO20053509L (enExample)
NZ (1) NZ540493A (enExample)
TW (1) TWI331036B (enExample)
WO (1) WO2005044245A1 (enExample)
ZA (1) ZA200504478B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60110219T2 (de) * 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
TWI331036B (en) * 2002-12-19 2010-10-01 Schering Corp Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
EP1622912B1 (en) * 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
ATE461932T1 (de) 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
EA200700707A1 (ru) 2004-09-22 2007-08-31 Х. Лундбекк А/С Производные 2-ациламинотиазола
US8455437B2 (en) * 2005-02-04 2013-06-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method to predict and prevent oxygen-induced inflammatory tissue injury
US7674912B2 (en) * 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
EP2258372B8 (en) 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. A2A antagonists for use in the treatment of motor disorders
EP1934227B1 (en) * 2005-09-19 2011-12-21 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
PE20070521A1 (es) 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
EP2499142B1 (en) 2009-11-09 2016-09-21 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
EP2509983B1 (en) 2009-11-16 2014-09-17 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
US8473582B2 (en) * 2009-12-16 2013-06-25 International Business Machines Corporation Disconnected file operations in a scalable multi-node file system cache for a remote cluster file system
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
ES2579949T3 (es) 2010-02-05 2016-08-17 Heptares Therapeutics Limited Derivados de 1,2,4-triazin-4-amina
AU2011306358B2 (en) * 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
WO2012135084A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2014101113A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
CN105025899B (zh) * 2012-12-28 2017-08-18 默沙东公司 具有A2A拮抗剂性质的杂二环取代的‑[1,2,4]三唑并[1,5‑c]喹唑啉‑5‑胺化合物
WO2014101120A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2018013951A1 (en) * 2016-07-15 2018-01-18 Northwestern University Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias
WO2019002606A1 (en) * 2017-06-30 2019-01-03 Selvita S.A. ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS
JP7391022B2 (ja) 2017-12-19 2023-12-04 インペティス・バイオサイエンシーズ・リミテッド がんの処置のための医薬組成物
IL275817B2 (en) * 2018-01-04 2024-04-01 Impetis Biosciences Ltd Tricyclic compounds, compositions and medicinal applications thereof
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
JP2022540583A (ja) * 2019-07-17 2022-09-16 テオン セラピューティクス，インク． アデノシンａ２ａ受容体アンタゴニスト及びその使用
US11806350B2 (en) * 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
WO1995003806A1 (en) * 1993-07-27 1995-02-09 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
US5933964A (en) * 1996-07-17 1999-08-10 Wahl Clipper Corporation Cutter blade for hair clippers
EP0975345A1 (en) 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
GB9819384D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9915437D0 (en) * 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
DE60110219T2 (de) 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
DE60231386D1 (de) 2001-04-09 2009-04-16 Neurosearch As Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
CA2459304A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
KR100687954B1 (ko) 2001-10-15 2007-02-27 쉐링 코포레이션 아데노신 Ａ2ａ 수용체 길항제로서의이미다조（4,3-ｅ）-1,2,4-트리아졸로（1,5-ｃ） 피리미딘
AR038366A1 (es) 2001-11-30 2005-01-12 Schering Corp Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion
IL161573A0 (en) 2001-11-30 2004-09-27 Schering Corp [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS
IL161716A0 (en) 2001-11-30 2004-09-27 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
KR101098209B1 (ko) * 2002-01-28 2011-12-23 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법
ES2310258T5 (es) * 2002-08-30 2012-05-31 Kyowa Hakko Kogyo Co., Ltd. Antagonistas de los receptores de adenosina A2A para tratar el síndrome de piernas inquietas o mioclono nocturno
TWI331036B (en) * 2002-12-19 2010-10-01 Schering Corp Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
EP1622912B1 (en) 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists

Similar Documents

Publication Publication Date Title
JP2011006431A5 (enExample)
HUS2200018I1 (hu) Drospirenont tartalmazó gyógyszerkészítmény, fogamzásgátlóként történõ alkalmazásra
LT3632919T (lt) Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuoto receptoriaus 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
DK2877574T3 (da) Alpha (1,2)-fucosyltransferaser egnet til anvendelse i fremstillingen af fucosylerede oligosaccharider
FR2962442B1 (fr) Composition stable de 2,3,3,3-tetrafluoropropene
CO6791606A2 (es) Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas
SG10201505282YA (en) Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
ZA201209632B (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
ITMI20111404A1 (it) Supporto per articolazioni umane.
EP2647381A4 (en) MELTING TABLET
EP3068442A4 (en) Bionanofluid for use as a contrast, imaging, disinfecting and/or therapeutic agent
HUE045724T2 (hu) GRPR antagonisták GRPR-pozitív rák kimutatására, diagnózisára és kezelésére
PT2655375E (pt) Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
EP3038466A4 (en) 2,2-difluorodioxolo a2a receptor antagonists
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
BR112012018402A2 (pt) "produto refratário com elevado teor de zircônio".
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
HRP20260138T1 (hr) Postupak priprave 2,3,3,3-tetrafluoropropena
EP2533763C0 (de) Dermatologische, pharmazeutische zusammensetzung geeignet für oligonukleotide
PL2623499T3 (pl) Pochodne 1,2,4-triazolonu
FR2953410B1 (fr) Compositions antivirales pharmaceutiques ou veterinaires
BR112012021455A2 (pt) formulação farmacêutica ou nutracêutica.
BR112014001425A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo